Nolato AB (publ) (NOLA-B.ST) | Investment Case

1. Company Snapshot

1.a. Company Description

Nolato AB (publ) develops, manufactures, and sells plastic, silicone, and thermoplastic elastomer products for medical technology, pharmaceutical, consumer electronics, telecom, automotive, and other industrial sectors in North America, Sweden, Asia, and other Europe region.The company offers consumables and reusable labware for clinical, chemical, forensic, research, and industrial testing laboratories; manufactures pipette tips, deep-well plates, microtubes, and PCR products; assemblies and post-processing services; and products for primary pharmaceutical packaging, as well as for solids, creams, and ophthalmic and customized production solutions.It designs, develops, and produces advanced components, subsystems, and ready-packaged electronics products, such as laser applications and ceramics, fitness trackers, loudspeaker systems, thermostats, webcams, and vaporiser heating products; automotive products; EMI shielding, thermal interface materials, and silicone sealing and damping solutions; and supplies plastic components and assemblies for food processing equipment, such as coffee machines and blenders.

The company was formerly known as Nordiska Latexfabriken i Torekov AB and changed its name to Nolato AB (publ) in 1982.Nolato AB (publ) was incorporated in 1938 and is headquartered in Torekov, Sweden.

Show Full description

1.b. Last Insights on NOLA

Nolato AB's recent performance was negatively impacted by the decline in European markets, with the STOXX Europe 600 Index ending lower and key indices like France's CAC 40 and Germany's DAX also declining. The company's ability to navigate economic fluctuations was compromised by the renewed trade and geopolitical uncertainties. Furthermore, the modest eurozone business activity growth and heightened optimism in the business outlook created a challenging environment for Nolato AB to operate in.

1.c. Company Highlights

Last Price	49.3
Change Percentage	-0.80%
Open	49.7
Previous Close	49.7
Market Cap ( Millions)	13280
Volume	46863
Year High	64.65
Year Low	46.8
M A 50	55.37
M A 200	58.27

FCF Yield	3.40%
Dividend Yield	3.04%
ROE	14.22%
Debt / Equity	33.62%
Net Debt / EBIDTA	86.61%
Price To Book	2.4
Price Earnings Ratio	17.09
Price To FCF	29.45
Price To sales	1.4
EV / EBITDA	9.21

2. Nolato's Q4 2025 Earnings: A Mixed Bag

Nolato's fourth-quarter 2025 sales reached SEK 2.3 billion, representing a 2% growth adjusted for currency fluctuations. The operating profit stood at SEK 236 million, with a margin of 10.4%. Earnings per share (EPS) came in at 0.561, falling short of analyst estimates of 0.73. For the full year 2025, sales increased by 2% adjusted for currency, with an operating profit rise of 11% and a margin of 11.3%. The company's EBITA margin for the full year improved by 1.4 percentage points, driven by pricing, cost adjustments, and supply chain efforts.

Publication Date: Mar -08

                                    📋 Highlights
                                    Total Sales Growth::
                                                Q4 sales reached SEK 2.3 billion (+2% adjusted for currency), with Medical Solutions up 5% (58% of group sales).
Operating Profit Margin::
                                                Q4 operating profit margin at 10.4% (SEK 236 million), down from prior year but 11% annual growth with 11.3% margin.
Engineered Solutions Challenges::
                                                Sales declined 1% adjusted for currency (SEK 1 billion), impacted by higher U.S. start-up costs and volatile precious metal prices.
Sustainability Progress::
                                                96% reduction in Scope 1/2 emissions and 30% cut in Scope 3 upstream emissions, supporting long-term M&A strategy.
Material Price Pressure::
                                                Sharp rise in silver prices (precious metals) impacted Engineered Solutions in Q4, with pricing adjustments ongoing to offset costs.

                                

Segment Performance

The Medical Solutions business area, accounting for 58% of group sales, grew by 5% adjusted for currency. Engineered Solutions, on the other hand, saw a 1% decline in sales. The business area's margin was affected by higher costs for new product start-ups in the U.S. and increased precious metal prices. According to Per-Ola Holmstrom, "the pricing of precious materials, mainly silver, has skyrocketed and will continue to affect the business area."

Valuation and Outlook

With a P/E Ratio of 17.7 and an EV/EBITDA of 9.51, Nolato's valuation appears reasonable. The company's ROE stands at 14.22%, indicating a decent return on equity. Analysts estimate revenue growth at 7.9% for the next year. Nolato's strong position in medical solutions and its favorable financial position, with a Net Debt / EBITDA of 0.87, enable it to pursue an intensified M&A agenda.

Sustainability and Strategy

Nolato has made significant strides in sustainable development, achieving a 96% reduction in Scope 1 and 2 emissions and a 30% reduction in Scope 3 upstream emissions. The company remains committed to its growth strategy, leveraging its broad customer base and long-standing customer relationships. With a continuous focus on medical solutions, Nolato is poised for future growth.

3. NewsRoom

Nolato AB (NLTBF) Q4 2025 Earnings Call Highlights: Resilient Growth Amid Currency Challenges

Feb -13

Source:

European Undervalued Small Caps With Insider Action For January 2026

Jan -28

Source:

Exploring Three Promising European Stocks with Strong Potential

Jan -02

Source:

Undervalued European Small Caps With Insider Buying For December 2025

Dec -30

Source:

Incap Oyj And 2 Other Undiscovered Gems In Europe

Dec -04

Source:

Exploring 3 Top Undervalued Small Caps In Global With Insider Activity

Dec -01

Source:

Insider Action On 3 Undervalued Small Caps In Global Market

Oct -31

Source:

Discovering Europe's Hidden Stock Gems for October 2025

Oct -31

Source:

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (5.60%)

6. Segments

Medical Solutions

Expected Growth: 5%

Nolato Medical Solutions' 5% growth is driven by increasing demand for medical devices, expansion into emerging markets, and strategic partnerships. Additionally, investments in R&D and manufacturing capabilities have improved efficiency and enabled the company to capitalize on trends such as minimally invasive surgeries and personalized medicine.

Industrial Solutions

Expected Growth: 7%

Nolato AB's Industrial Solutions segment growth is driven by increasing demand for medical devices, electrification of vehicles, and rising adoption of renewable energy sources. The company's expertise in silicone and plastic component manufacturing, coupled with its strong customer relationships and investments in R&D, have enabled it to capitalize on these trends, resulting in a 7% growth rate.

Integrated Solutions

Expected Growth: 5%

Nolato AB's Integrated Solutions segment growth is driven by increasing demand for complex medical devices, strategic acquisitions, and expansion into high-growth markets. Additionally, the company's focus on innovation, operational efficiency, and customer partnerships contribute to its 5% growth rate.

7. Detailed Products

Medical Solutions

Nolato AB provides medical solutions such as medical devices, diagnostic equipment, and pharmaceutical packaging.

Integrated Solutions

Nolato AB offers integrated solutions for industrial and consumer applications, including electronics, automotive, and industrial components.

Industrial Solutions

Nolato AB provides industrial solutions such as industrial components, machinery, and equipment.

Consumer Solutions

Nolato AB offers consumer solutions such as consumer electronics, appliances, and packaging solutions.

8. Nolato AB (publ)'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Nolato AB (publ) is medium due to the availability of alternative products and services in the market.

Bargaining Power Of Customers

The bargaining power of customers is high due to the concentration of customers in the automotive and medical industries, giving them significant negotiating power.

Bargaining Power Of Suppliers

The bargaining power of suppliers is low due to the company's large scale of operations and diversified supplier base, reducing dependence on individual suppliers.

Threat Of New Entrants

The threat of new entrants is low due to the high barriers to entry, including significant capital requirements and regulatory hurdles.

Intensity Of Rivalry

The intensity of rivalry is high due to the competitive nature of the industry, with several established players competing for market share.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	23.44%
Debt Cost	4.30%
Equity Weight	76.56%
Equity Cost	8.80%
WACC	7.75%
Leverage	30.61%

11. Quality Control: Nolato AB (publ) passed 4 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Inefficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Mercedes-Benz

A-Score: 6.4/10

Value: 7.2

Growth: 8.8

Quality: 5.9

Yield: 2.5

Momentum: 9.5

Volatility: 4.3

1-Year Total Return ->

GPI

A-Score: 6.0/10

Value: 5.4

Growth: 6.8

Quality: 3.1

Yield: 8.1

Momentum: 8.5

Volatility: 4.0

1-Year Total Return ->

Nolato

A-Score: 5.4/10

Value: 3.2

Growth: 4.3

Quality: 5.7

Yield: 7.5

Momentum: 6.0

Volatility: 5.7

1-Year Total Return ->

Arendals Fossekompani

A-Score: 5.3/10

Value: 6.0

Growth: 4.8

Quality: 7.6

Yield: 5.0

Momentum: 3.0

Volatility: 5.3

1-Year Total Return ->

Bergman & Beving

A-Score: 4.1/10

Value: 4.8

Growth: 3.3

Quality: 2.7

Yield: 3.1

Momentum: 5.5

Volatility: 5.3

1-Year Total Return ->

BayWa

A-Score: 3.5/10

Value: 10.0

Growth: 4.3

Quality: 5.4

Yield: 1.2

Momentum: 0.0

Volatility: 0.0

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

18.15%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

7.75%

Nolato AB (publ) - SE0015962477

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on NOLA

1.c. Company Highlights

Expensive

Lower Growth

Higher Yield

Earnings Beats

Revenues Beats

Strong Momentum

Average Yield

Stable Momentum

Fairly Valued

Average Growth

Earnings Miss

Revenues Miss

Average Quality

2. Nolato's Q4 2025 Earnings: A Mixed Bag

Segment Performance

Valuation and Outlook

Sustainability and Strategy

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (5.60%)

6. Segments

Medical Solutions

Expected Growth: 5%

Industrial Solutions

Expected Growth: 7%

Integrated Solutions

Expected Growth: 5%

7. Detailed Products

Medical Solutions

Integrated Solutions

Industrial Solutions

Consumer Solutions

8. Nolato AB (publ)'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Nolato AB (publ) passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

49.3$

Current Price

49.3$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA